Use of dendritic cells to modulate immune responses

February 20, 2013

Dendritic cells (DC) are recognized as the most potent antigen presenting cells with the unique ability to initiate and maintain primary immune responses.

The overall aim of my research project is to further unravel the mechanisms by which DC modulate T cell responses, both in autoimmunity as well as tumor immunity. Four subprojects will be addressed:

  • analyze dysregulation of DC in autoimmune diseases using Sjögren’s syndrome as a model
  • improve tumor vaccination strategies with DC
  • unravel role of DC in development of squamous cell carcinoma in renal transplant recipients
  • disclose function of transcription factor ESE-3 in DC

Our results will lead to a better understanding of the cellular mechanisms involved in antigen presentation, T cell stimulation and tolerance induction, thereby revealing new tools for diagnosis and targets for therapy of patients with cancer, autoimmune and infectious diseases as well as patients undergoing stem cell transplantation. Thus, it might lead to an increased survival and better quality of life for patients.

Group
Silke Appel (Project leader, BFS)
Arnt-Ove Hovden (Postdoc, kreftforeningen)
Petra Vogelsang (PhD fellow, UiB)
Lene Frøyen Sandvik (PhD fellow, UiB)
Roman Volchenkov (PhD fellow, UiB)
Florian Sprater (PhD fellow, BFS)
Dagny Ann Sandnes (Department Engineer, BFS)
Marie Karlsen (Department Engineer, BFS)
Magne Olsen (Master student i Medisinsk Cellebiologi)

Name: Silke Appel
Aget: 35 years
PhD: Dr. rer. nat. (PhD), Freie Universität Berlin 2001
Citizenship: German
Department: Broegelmanns Forskningslaboratorium, Gades institutt; Medisinsk-odontologisk fakultetet
Grant from BFS: 7.348.000 NOK
Additional funding: 7.858.000 NOK
Start/end of project: 2008-2012
Web: Link to project webpage

Comments are closed.